Lung cancer trials in Ukraine

In Ukraine 11 Also abroad 2729

11 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Dnipro, Kropyvnytskyi, Kyiv, Lutsk, Rivne, Uzhhorod
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 1/2Taking people
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Where
Kyiv
Age
18 years and over
People
334 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01
Phase 3Taking people
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Where
Cherkasy, Chernivtsi, Ivano-Frankivsk, Kropyvnytskyi, Kryvyi Rih, Kyiv, Lutsk, Lviv, Odesa, Rivne, Vinnytsia
Age
18 years and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00
Phase 3Taking people
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Where
Chernivtsi, Ivano-Frankivsk, Kropyvnytskyi, Kryvyi Rih, Kyiv, Lutsk, Lviv, Odesa, Rivne, Vinnytsia
Age
18 years and over
People
310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00
Phase 1Taking people
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Where
Chernivtsi, Lutsk
Age
18 years and over
People
120 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT07080242
Phase 1/2Taking people
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Where
Cherkasy, Ivano-Frankivsk, Rivne, Uzhhorod
Age
18 years and over
People
450 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00
No phaseTaking people
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Where
Cherkasy, Ivano-Frankivsk, Rivne, Uzhhorod
Age
18 years and over
People
1,065 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165798
Phase 3Taking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Cherkasy, Chernivtsi, Ivano-Frankivsk, Kiev, Kropyvnytskyi, Kryvyi Rih, Kyiv, Lutsk, Lviv, Rivne, Vinnytsia
Age
18 years and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
Phase 3Taking people
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Where
Chernivtsi, Kyiv, Lviv, Odesa, Rivne, Zhytomyr
Age
18 years and over
People
675 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00
Phase 2Taking people
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Where
Cherkasy, Chernivtsi, Ivano-Frankivsk, Kyiv, Vinnytsia
Age
18 years and over
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06731907 · EU 2024-515772-12-00
Phase 2Taking people
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Where
Cherkasy, Ivano-Frankivsk, Kropyvnytskyi, Kryvyi Rih, Kyiv, Lviv, Uzhhorod, Vinnitsya
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00